MX338551B - Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa. - Google Patents

Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa.

Info

Publication number
MX338551B
MX338551B MX2013005833A MX2013005833A MX338551B MX 338551 B MX338551 B MX 338551B MX 2013005833 A MX2013005833 A MX 2013005833A MX 2013005833 A MX2013005833 A MX 2013005833A MX 338551 B MX338551 B MX 338551B
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
casein kinase
pyridine compounds
fused pyridine
novel fused
Prior art date
Application number
MX2013005833A
Other languages
English (en)
Spanish (es)
Other versions
MX2013005833A (es
Inventor
Todd W Butler
Ramalakshmi Y Chandrasekaran
Scot R Mente
Chakrapani Subramanyam
Travis T Wagner
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2013005833A publication Critical patent/MX2013005833A/es
Publication of MX338551B publication Critical patent/MX338551B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
MX2013005833A 2010-12-20 2011-12-06 Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa. MX338551B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061425213P 2010-12-20 2010-12-20
PCT/IB2011/055489 WO2012085721A1 (en) 2010-12-20 2011-12-06 Novel fused pyridine compounds as casein kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2013005833A MX2013005833A (es) 2013-07-05
MX338551B true MX338551B (es) 2016-04-20

Family

ID=45446116

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005833A MX338551B (es) 2010-12-20 2011-12-06 Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa.

Country Status (23)

Country Link
US (1) US8536164B2 (enExample)
EP (2) EP2654750B1 (enExample)
JP (2) JP5684923B2 (enExample)
KR (1) KR101590236B1 (enExample)
CN (1) CN103260622B (enExample)
AR (1) AR084412A1 (enExample)
AU (1) AU2011346733C1 (enExample)
CA (1) CA2819961C (enExample)
CY (2) CY1118772T1 (enExample)
DK (2) DK3181133T3 (enExample)
ES (2) ES2744099T3 (enExample)
HR (2) HRP20170484T1 (enExample)
HU (2) HUE032405T2 (enExample)
IL (1) IL226948A (enExample)
LT (2) LT3181133T (enExample)
MX (1) MX338551B (enExample)
PL (2) PL2654750T3 (enExample)
PT (2) PT2654750T (enExample)
RS (2) RS59098B1 (enExample)
SG (1) SG190802A1 (enExample)
SI (2) SI2654750T1 (enExample)
WO (1) WO2012085721A1 (enExample)
ZA (1) ZA201303453B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5784620B2 (ja) * 2009-10-28 2015-09-24 ファイザー・インク カゼインキナーゼ阻害剤としてのイミダゾール誘導体
US9938269B2 (en) * 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
CN104837844B (zh) * 2012-12-21 2017-08-29 百时美施贵宝公司 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
WO2015163446A1 (ja) * 2014-04-25 2015-10-29 協和発酵キリン株式会社 イミダゾール化合物の製造方法
JP2017222576A (ja) * 2014-10-31 2017-12-21 石原産業株式会社 有害生物防除剤
CN107365315B (zh) * 2016-05-11 2024-08-09 国药集团国瑞药业有限公司 一种吡唑类化合物、其晶型及其制备方法
US10973820B2 (en) * 2017-12-13 2021-04-13 Facio Intellectual Property B.V. Compounds for treatment of diseases related to DUX4 expression
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
EP4126878A4 (en) * 2020-03-27 2024-07-10 Gritscience Biopharmaceuticals Co., Ltd. COMPOUNDS AS CASEIN KINASE INHIBITORS
WO2021190616A1 (en) * 2020-03-27 2021-09-30 Gritscience Biopharmaceuticals Co., Ltd. Methods for inhibiting casein kinases
AR122711A1 (es) 2020-06-25 2022-09-28 Alchemedicine Inc COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA
CN111808102B (zh) * 2020-08-03 2021-12-31 南通大学 一种3-甲氧基-6,7-二氢-5H-吡咯并[3,4-b]吡啶盐酸盐及其合成方法
JP2023541463A (ja) * 2020-09-17 2023-10-02 ヤンセン ファーマシューティカ エヌ.ベー. カゼインキナーゼ1デルタモジュレーター
WO2022058920A1 (en) * 2020-09-17 2022-03-24 Janssen Pharmaceutica Nv Casein kinase 1 delta modulators
EP4251149A4 (en) * 2020-11-24 2024-10-30 Merck Sharp & Dohme LLC MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
CN116888126A (zh) * 2020-12-15 2023-10-13 北京原基华毅生物科技有限公司 一种酪蛋白激酶抑制剂的化合物
US20230053307A1 (en) * 2021-07-19 2023-02-16 Buddhist Tzu Chi Medical Foundation Method for preventing or treating skin disorders and conditions
CN119487030A (zh) * 2022-06-14 2025-02-18 北京原基华毅生物科技有限公司 作为酪蛋白激酶抑制剂的化合物的盐和/或晶形
CN117362303A (zh) * 2022-07-02 2024-01-09 黑龙江联顺生物科技有限公司 一种生物素中间体环酐的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0151962A3 (en) 1984-01-25 1985-10-02 Beecham Group Plc Pyrazolopyridine derivatives
NZ501112A (en) * 1997-05-22 2002-10-25 G Substituted pyrazoles as p38 kinase inhibitors
US6610688B2 (en) * 1999-12-21 2003-08-26 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
HRP20150832T1 (hr) 2005-06-22 2015-09-25 Chemocentryx, Inc. Spojevi azaindazola i postupci njihove upotrebe
WO2007140213A1 (en) 2006-05-26 2007-12-06 Forest Laboratories Holdings Limited Pyridoazepine derivatives
EP2308866A1 (de) * 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
JP5784620B2 (ja) * 2009-10-28 2015-09-24 ファイザー・インク カゼインキナーゼ阻害剤としてのイミダゾール誘導体

Also Published As

Publication number Publication date
KR101590236B1 (ko) 2016-01-29
EP2654750B1 (en) 2017-03-08
PL3181133T3 (pl) 2019-12-31
IL226948A (en) 2017-04-30
ES2623387T3 (es) 2017-07-11
PT3181133T (pt) 2019-09-16
JP2014503544A (ja) 2014-02-13
DK3181133T3 (da) 2019-08-26
HK1188145A1 (en) 2014-04-25
CY1118772T1 (el) 2017-07-12
WO2012085721A1 (en) 2012-06-28
SI3181133T1 (sl) 2019-10-30
HRP20191469T1 (hr) 2019-11-29
HUE032405T2 (en) 2017-09-28
US20120157440A1 (en) 2012-06-21
AR084412A1 (es) 2013-05-15
JP5684923B2 (ja) 2015-03-18
US8536164B2 (en) 2013-09-17
LT2654750T (lt) 2017-05-10
JP2015107992A (ja) 2015-06-11
AU2011346733A1 (en) 2013-07-18
CY1122062T1 (el) 2020-11-25
ES2744099T3 (es) 2020-02-21
PT2654750T (pt) 2017-05-04
DK2654750T3 (en) 2017-05-01
PL2654750T3 (pl) 2017-07-31
CA2819961A1 (en) 2012-06-28
LT3181133T (lt) 2019-09-25
EP3181133B1 (en) 2019-07-24
AU2011346733C1 (en) 2015-12-24
HUE047089T2 (hu) 2020-04-28
ZA201303453B (en) 2014-07-30
CN103260622A (zh) 2013-08-21
HRP20170484T1 (hr) 2017-06-02
EP2654750A1 (en) 2013-10-30
AU2011346733B2 (en) 2015-08-13
EP3181133A1 (en) 2017-06-21
CN103260622B (zh) 2015-05-13
SG190802A1 (en) 2013-07-31
RS55897B1 (sr) 2017-08-31
KR20130121126A (ko) 2013-11-05
CA2819961C (en) 2015-08-18
JP5876596B2 (ja) 2016-03-02
SI2654750T1 (sl) 2017-04-26
RS59098B1 (sr) 2019-09-30
MX2013005833A (es) 2013-07-05

Similar Documents

Publication Publication Date Title
MX338551B (es) Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa.
IN2012DN03182A (enExample)
IN2015DN01119A (enExample)
UA108926C2 (ru) LibreOffice? [2,3-D] +" +" !+
IN2014MN02598A (enExample)
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
WO2014045162A8 (en) ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS
MY149731A (en) Compounds
MY172924A (en) Neprilysin inhibitors
PH12014501542B1 (en) Substituted pyrrolidine -2- carboxamides
MX2012002876A (es) Derivados de dihidropteridinona, proceso para su preparacion y uso farmaceutico.
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
GB201209587D0 (en) Therapeutic compounds
PH12015500063A1 (en) Azaindole derivatives which act as pi3k inhibitors
GB201101517D0 (en) Receptor antagonists
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
MX2012002369A (es) Formas de anhidrato de un derivado de piridina.
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
GEP20135960B (en) New method of synthesis of ivabradine and pharmaceutically acceptable acid-additive salts thereof
PH12012500992A1 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
WO2011125006A3 (en) Sultam compounds
MX2015006806A (es) Procedimiento para preparar 4-(ciclopropilmetoxi)-n-(3,5-dicloro-1 -oxido-4-piridil)-5-metoxipiridina-2-carboxamida.
MX2011012329A (es) Nuevas sales farmaceuticamente aceptables de 4-(1h-imidazol-4-ilme til)piridina y sus usos terapeuticos.

Legal Events

Date Code Title Description
FG Grant or registration